2. Academic Validation
  3. Triggering Breast Cancer Apoptosis via Cyclin-Dependent Kinase Inhibition and DNA Damage by Novel Pyrimidinone and 1,2,4-Triazolo[4,3- a]pyrimidinone Derivatives

Triggering Breast Cancer Apoptosis via Cyclin-Dependent Kinase Inhibition and DNA Damage by Novel Pyrimidinone and 1,2,4-Triazolo[4,3- a]pyrimidinone Derivatives

  • ACS Omega. 2024 May 6;9(19):21042-21057. doi: 10.1021/acsomega.4c00466.
Mohamed N Abd Al Moaty 1,  Yeldez El Kilany 1,  Laila F Awad 1,  Saied M Soliman 1,  Assem Barakat 2,  Nihal A Ibrahim 1,  Marwa M Abu-Serie 3,  Matti Haukka 4,  Amira El-Yazbi 5,  Mohamed Teleb 6
Affiliations

Affiliations

  • 1 Chemistry Department, Faculty of Science, Alexandria University, Alexandria 21321, Egypt.
  • 2 Department of Chemistry, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.
  • 3 Medical Biotechnology Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Alexandria 21934, Egypt.
  • 4 Department of Chemistry, University of Jyväskylä, P.O. Box 35, FI-40014 Jyväskylä , Finland.
  • 5 Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
  • 6 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
PMID: 38764636 DOI: 10.1021/acsomega.4c00466
Abstract

Combinations of apoptotic inducers are common clinical practice in breast Cancer. However, their efficacy is limited by the heterogeneous pharmacokinetic profiles. An advantageous alternative is merging their molecular entities in hybrid multitargeted scaffolds exhibiting synergistic activities and uniform distribution. Herein, we report apoptotic inducers simultaneously targeting DNA and CDK-2 (cyclin-dependent kinase-2) inspired by studies revealing that CDK-2 inhibition sensitizes breast Cancer to DNA-damaging agents. Accordingly, rationally substituted pyrimidines and triazolopyrimidines were synthesized and assayed by MTT against MCF-7, MDA-MB231, and Wi-38 cells compared to doxorubicin. The N-(4-amino-2-((2-hydrazinyl-2-oxoethyl)thio)-6-oxo-1,6-dihydropyrimidin-5-yl)acetamide 5 and its p-nitrophenylhydrazone 8 were the study hits against MCF-7 (IC50 = 0.050 and 0.146 μM) and MDA-MB231 (IC50 = 0.826 and 0.583 μM), induced DNA damage at 10.64 and 30.03 nM, and inhibited CDK-2 (IC50 = 0.172 and 0.189 μM). 5 induced MCF-7 Apoptosis by 46.75% and disrupted cell cycle during S phase. Docking and MD simulations postulated their stable key interactions.

Figures
Products